IDH1 and central nervous system cancer: Since IDH1/2mut occurs early in gliomagenesis, and the histone/DNA hypermethylation state of IDH1/2mut gliomas is largely retained even during disease progression [7–10], there is a possibility that epigenetic modifiers may be particularly effective against IDH1/2mut glioma.